F2RL1 and heart failure: We hypothesize that EGCG’s ability to inhibit PAR-2, thereby downregulating NF-κB and related inflammatory pathways, suggests that EGCG could be a potent inhibitor of heart failure and its associated cardio-oncological outcomes.